Pharmacogenetics affects the efficacy and adverse effect risk of many psychiatric medications. Patients with depression can significantly benefit from pharmacogenetic testing. The Abomics pharmacogenetic interpretation report makes understanding and applying the results to clinical practice fast and easy. See a sample report.
Polypharmacy predisposes the patient to adverse drug reactions and drug-drug interactions and can make medication decisions challenging for the treating doctor. Pharmacogenetic testing supports medication decision-making.
Clopidogrel is used to prevent venous thromboembolism, but its effects may be insufficient in up to 30 % of patients. With pharmacogenetic testing you can predict the patient’s drug response.
Pharmacogenetics affects the effectiveness and safety of many medicines depending on the patient’s genetics. Clopidogrel, which is often prescribed to patients after a stroke, is one of these medicines.
Abomics, Abomics PGx, GeneRx, GeneAccount are registered or non-registered trademarks of Abomics Oy in various countries.
